Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | CHRNB2 | P17787 | 3/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 3/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | FYN | P06241 | 1/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.37 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.37 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.37 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22641245 | 0.83 | PTGS2 (0.48) | NPC1POLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL2746304 | 0.83 | NPC1 (0.44) | NPC1POLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL27677964 | 0.81 | NPC1 (0.40) | NPC1POLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL16246672 | 0.81 | NPC1 (0.40) | NPC1POLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL26992430 | 0.80 | GAA (0.51) | NPC1POLBRAB9AHSD17B10ALOX15 | |
| SCHEMBL21499282 | 0.79 | NPC1 (0.48) | NPC1POLBRAB9AHSD17B10ALOX15 | |
| SCHEMBL19330511 | 0.79 | NPC1 (0.48) | NPC1POLBRAB9AHSD17B10ALOX15 | |
| SCHEMBL2746674 | 0.79 | MAPT (0.40) | NPC1POLBRAB9ACHRNB2CHRNA4 | |
| SCHEMBL10112979 | 0.78 | NPC1 (0.47) | NPC1POLBRAB9AHSD17B10ALOX15 | |
| SCHEMBL24798987 | 0.77 | NPC1 (0.38) | NPC1POLBRAB9ACHRNB2CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3305778-B1 | INHIBITORS OF PLASMA KALLIKREIN | KALVISTA PHARMACEUTICALS LTD (GB) | 2022-01-19 | — | — | EP | disclosed |
| CN-105452240-B | Hete rocyclic derivatives | 卡尔维斯塔制药有限公司 | 2018-06-26 | — | — | CN | disclosed |
| EP-3305778-A1 | INHIBITORS OF PLASMA KALLIKREIN | Kalvista Pharmaceuticals Limited (GB) | 2018-04-11 | — | — | EP | disclosed |
| EP-2999697-B1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LTD (GB) | 2017-04-19 | — | — | EP | disclosed |
| US-9533987-B2 | Heterocyclic derivates | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2017-01-03 | — | — | US | disclosed |
| WO-2016083816-A1 | N-((HETEROARYLMETHYL)-HETEROARYL-CARBOXAMIDE DERIVATIVES AS PLASMA KALLIKREIN INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-06-02 | — | — | WO | disclosed |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2016-04-21 | — | — | US | disclosed |
| EP-2999697-A1 | HETEROCYCLIC DERIVATES | Kalvista Pharmaceuticals Limited (GB) | 2016-03-30 | — | — | EP | disclosed |
| CN-105452240-A | Heterocyclic derivates | KALVISTA PHARMACEUTICALS LTD | 2016-03-30 | — | — | CN | disclosed |
| WO-2014188211-A1 | HETEROCYCLIC DERIVATES | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2014-11-27 | — | — | WO | disclosed |
| US-7709649-B2 | Multi-substituted pyridyl sulfoximines and their use as insecticides | DOW AGROSCIENCES LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709649-B2 | Multi-substituted pyridyl sulfoximines and their use as insecticides | DOW AGROSCIENCES LLC (US) | 2010-05-04 | — | — | US | disclosed |
| US-7709649-B2 | Multi-substituted pyridyl sulfoximines and their use as insecticides | DOW AGROSCIENCES LLC (US) | 2010-05-04 | — | — | US | disclosed |
| CN-101535263-A | Polysubstituted pyridyl sulfoximines and their use as pesticides | DOW AGROSCIENCES LLC (US) | 2009-09-16 | — | — | CN | disclosed |
| EP-2079697-A1 | MULTI-SUBSTITUTED PYRIDYL SULFOXIMINES AND THEIR USE AS INSECTICIDES | Dow AgroSciences LLC (US) | 2009-07-22 | — | — | EP | disclosed |
| WO-2008057129-A1 | MULTI-SUBSTITUTED PYRIDYL SULFOXIMINES AND THEIR USE AS INSECTICIDES | DOW AGROSCIENCES LLC (US) | 2008-05-15 | — | — | WO | disclosed |
| WO-2008057129-A1 | MULTI-SUBSTITUTED PYRIDYL SULFOXIMINES AND THEIR USE AS INSECTICIDES | DOW AGROSCIENCES LLC (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080108667-A1 | Multi-substituted pyridyl sulfoximines and their use as insecticides | CORTEVA AGRISCIENCE LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108667-A1 | Multi-substituted pyridyl sulfoximines and their use as insecticides | CORTEVA AGRISCIENCE LLC | 2008-05-08 | — | — | US | disclosed |
| US-20080108667-A1 | Multi-substituted pyridyl sulfoximines and their use as insecticides | CORTEVA AGRISCIENCE LLC | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080108667-A1 | Multi-substituted pyridyl sulfoximines and their use as insecticides | PIR, PNPO, PRDX4 | NPC1 4881/4885POLB 3365/4885RAB9A 2655/4885 |
| US-20160108036-A1 | HETEROCYCLIC DERIVATES | BDKRB1, KLKB1, BDKRB2 | NPC1 1620/4885POLB 3416/4885RAB9A 1461/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.